You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Recreational drugs are among the most powerful demonstrations of a central claim in biological psychology: that behaviour, mood and perception are the outward expression of chemical events at the synapse. Every psychoactive drug — from the caffeine in a cup of coffee to heroin — produces its effects by interfering, at a molecular level, with the process of synaptic transmission described in the previous lesson. This lesson explains how that interference works. It distinguishes agonists (drugs that enhance neurotransmission) from antagonists (drugs that block it), sets out the specific mechanisms by which drugs act — stimulating or blocking receptors, increasing neurotransmitter release, blocking reuptake and inhibiting the enzymes that break neurotransmitters down — and applies these mechanisms to a set of named recreational drugs (nicotine, cocaine, amphetamines and MDMA, alcohol and cannabis). Running through all of this is the dopamine reward pathway, the mesolimbic circuit that most recreational drugs converge on, and which supplies the biological account of why drugs are reinforcing and how repeated use leads to tolerance and dependence. This is a distinctively Edexcel emphasis: the specification treats recreational drugs as an explicit application of neurotransmission, so a precise, mechanism-led understanding is directly examinable.
Key Definition: A recreational drug is a psychoactive substance taken for its effects on mood, perception or consciousness rather than for medical treatment. Psychoactive means the drug crosses the blood–brain barrier and alters neural activity, and it does so by modifying one or more stages of synaptic transmission.
This lesson addresses the Edexcel 9PS0 — Paper 1, Topic 3: Biological Psychology content on the effect of recreational drugs on the transmission process in the brain. You should be able to describe (AO1) how drugs alter synaptic transmission through the distinction between agonists and antagonists and the specific mechanisms of receptor stimulation and blockade, increased neurotransmitter release, reuptake blockade and enzyme inhibition, and how the dopamine reward pathway underpins the reinforcing effects of drugs. You should be able to apply (AO2) this knowledge to described scenarios — identifying the likely mechanism of a named or novel drug, or predicting the synaptic consequences of a described drug action. You should be able to evaluate (AO3) the neurochemical account of drug action, including the correlation-versus-causation problem in human drug research, the reductionism of a purely synaptic explanation, the use of animal models, and the practical value of the account for treating dependence.
Connects to…
The single most important organising idea in the pharmacology of recreational drugs is the distinction between drugs that enhance neurotransmission and drugs that reduce it.
Key Definition: An agonist is a drug that enhances or mimics the action of a neurotransmitter, increasing its effect at the synapse. An antagonist is a drug that blocks or reduces the action of a neurotransmitter, decreasing its effect at the synapse.
An agonist ultimately produces more postsynaptic activity in a given neurotransmitter system; an antagonist produces less. Crucially, however, a drug can achieve either outcome through several different molecular routes. An agonist need not itself bind the receptor — it might instead increase the amount of neurotransmitter available in the cleft (by boosting release, blocking reuptake or inhibiting the enzyme that degrades it), all of which raise the neurotransmitter's effect indirectly. This is why "agonist versus antagonist" (the net effect) and the "mechanism of action" (the route) are two separate questions, and a strong answer keeps them distinct.
A further subtlety is worth grasping early. Because a neurotransmitter's effect depends on the receptor it binds — the same chemical can be excitatory at one receptor subtype and inhibitory at another, as the previous lesson established — the behavioural consequence of an agonist is not automatically "more excitation." An agonist at an inhibitory system (for example, a drug that enhances GABA, the main inhibitory neurotransmitter) produces more inhibition and therefore a sedating, calming effect. So an agonist enhances a neurotransmitter's action; whether that action is stimulating or calming depends on which system is being enhanced.
Recreational and therapeutic drugs act at one or more discrete points in the synaptic cycle. The table below maps each mechanism onto the stage of transmission it targets and onto its net effect.
| Mechanism | Stage of transmission targeted | Net effect | Typical classification | Example |
|---|---|---|---|---|
| Receptor stimulation | Postsynaptic receptor binding | Mimics the neurotransmitter → more effect | Agonist | Nicotine (at ACh receptors) |
| Receptor blockade | Postsynaptic receptor binding | Prevents binding → less effect | Antagonist | Many antipsychotics (at dopamine receptors) |
| Increased release | Neurotransmitter release into cleft | More neurotransmitter available → more effect | Agonist | Amphetamines (dopamine) |
| Reuptake blockade | Clearance (reuptake) | Neurotransmitter lingers in cleft → more effect | Agonist (indirect) | Cocaine (dopamine) |
| Enzyme inhibition | Clearance (enzymatic breakdown) | Less degradation → more effect | Agonist (indirect) | MAO inhibitors (monoamines) |
The most direct way to enhance a neurotransmitter system is to introduce a molecule that is shaped closely enough to the neurotransmitter to bind its postsynaptic receptor and activate it. Because binding is highly specific — the "key in a lock" from the previous lesson — a drug that fits the lock can turn it, opening the receptor's ion channel just as the natural neurotransmitter would. Such a drug is a direct agonist. Nicotine is the classic recreational example: its shape allows it to bind and activate a class of acetylcholine receptor (the nicotinic receptors, named after it), stimulating them directly.
An antagonist works by occupying the receptor without activating it — it fits the lock but does not turn it, and by sitting there it prevents the natural neurotransmitter from binding. The result is reduced neurotransmission in that system. Antagonists are more prominent among therapeutic drugs (for instance, dopamine-receptor antagonists used to treat schizophrenia) than among recreational drugs, but the mechanism is essential background: it is the mirror image of receptor stimulation and completes the agonist/antagonist picture.
Rather than acting at the receptor, some drugs act on the presynaptic neuron to increase the amount of neurotransmitter dumped into the cleft. If more neurotransmitter molecules are released, more receptors are bound and the postsynaptic effect is amplified — an indirect agonist action. Amphetamines act largely this way on dopamine: they cause dopamine to be released into the synapse in abnormally large quantities (and can even reverse the reuptake transporter so that it pumps dopamine out rather than in), flooding the cleft.
Recall that one of the routes by which a signal is terminated is reuptake — the reabsorption of neurotransmitter back into the presynaptic neuron by a transporter protein. A drug that blocks this transporter leaves the neurotransmitter stranded in the cleft, where it continues to stimulate postsynaptic receptors for longer, prolonging and intensifying the signal. This too is an indirect agonist mechanism. Cocaine is the archetype: it blocks the dopamine transporter (and, to a lesser extent, the serotonin and noradrenaline transporters), so dopamine accumulates in the synapse. The same principle, applied therapeutically, is how selective serotonin reuptake inhibitors (SSRIs) raise serotonin to treat depression — a direct link between recreational and clinical pharmacology.
The other clearance route is enzymatic breakdown: enzymes in or near the synapse degrade neurotransmitter molecules so the signal is brief. A drug that inhibits such an enzyme allows the neurotransmitter to persist and accumulate — again an indirect agonist. The clinical example is the monoamine oxidase (MAO) inhibitors: by blocking the MAO enzyme that breaks down monoamines (dopamine, serotonin, noradrenaline), they raise the levels of these neurotransmitters. This mechanism also connects forward to the aggression lessons, where the gene coding for MAO-A is implicated in impulsive aggression precisely because it governs how quickly these neurotransmitters are cleared.
The flowchart below summarises how the five mechanisms map onto the synapse and onto the agonist/antagonist outcome.
flowchart TD
A[Drug enters synapse] --> B{Where does it act?}
B -->|Postsynaptic receptor| C{Activates receptor?}
C -->|Yes - mimics NT| D[Receptor stimulation<br/>AGONIST]
C -->|No - blocks receptor| E[Receptor blockade<br/>ANTAGONIST]
B -->|Presynaptic release| F[Increased NT release<br/>AGONIST - indirect]
B -->|Reuptake transporter| G[Reuptake blockade<br/>NT lingers in cleft<br/>AGONIST - indirect]
B -->|Degrading enzyme| H[Enzyme inhibition<br/>less breakdown<br/>AGONIST - indirect]
The reason so many recreational drugs are reinforcing — the reason people take them repeatedly despite harm — is best explained by their convergent action on a single circuit: the mesolimbic dopamine reward pathway.
Key Definition: The dopamine reward pathway (mesolimbic pathway) is a circuit running from the ventral tegmental area (VTA) in the midbrain to the nucleus accumbens and on to the prefrontal cortex. Dopamine released along this pathway signals reward and reinforces the behaviours that produced it.
This pathway evolved to reinforce naturally adaptive behaviours — eating, drinking, sex, social bonding. When such a behaviour occurs, dopamine-releasing neurons in the VTA fire, releasing dopamine into the nucleus accumbens, and this dopamine surge is experienced as pleasure and, more importantly, tags the preceding behaviour as "worth repeating." In this way the pathway is the brain's teaching signal for survival-relevant actions.
Recreational drugs hijack this system. Whatever their individual mechanisms — nicotine stimulating receptors on VTA neurons, cocaine blocking dopamine reuptake in the nucleus accumbens, amphetamines forcing dopamine release, alcohol and cannabis modulating the VTA indirectly — the shared downstream consequence is a surge of dopamine in the nucleus accumbens that is far larger and more reliable than any natural reward produces. The circuit therefore "learns" that the drug is enormously rewarding, and it does so more powerfully than it learns about food or company. This is the biological heart of why drugs are reinforcing: they generate an artificial reward signal that the reward system is not equipped to discount.
The research most associated with mapping this system in humans is that of Nora Volkow and colleagues, whose PET imaging work has repeatedly shown that addictive drugs raise dopamine in the striatum and that, in people with long-term dependence, dopamine-receptor (D2) availability is reduced — a finding central to the account of tolerance below.
flowchart LR
A[Ventral Tegmental Area<br/>VTA] -->|dopamine| B[Nucleus Accumbens]
B --> C[Prefrontal Cortex]
D[Drug taken] -.hijacks.-> A
B --> E[Large dopamine surge<br/>= reward signal]
E --> F[Behaviour reinforced<br/>= drug-seeking learned]
The value of the framework above is that it lets us analyse any drug by asking three questions: which neurotransmitter system, what mechanism, and what net effect. The table and the notes that follow apply this to the named recreational drugs.
| Drug | Primary system(s) | Mechanism | Net effect | Dopamine link |
|---|---|---|---|---|
| Nicotine | Acetylcholine (nicotinic) | Direct receptor stimulation (agonist) | Stimulant; raises alertness | Stimulates ACh receptors on VTA neurons → dopamine release |
| Cocaine | Dopamine (also serotonin, noradrenaline) | Reuptake blockade (indirect agonist) | Powerful stimulant; euphoria | Dopamine accumulates directly in nucleus accumbens |
| Amphetamines | Dopamine (also noradrenaline) | Increased release + reuptake reversal (indirect agonist) | Strong stimulant | Floods synapse with dopamine |
| MDMA (ecstasy) | Serotonin (also dopamine) | Increased release + reuptake reversal | Stimulant + empathogen; mood elevation | Massive serotonin release; some dopamine |
| Alcohol | GABA (enhances) + glutamate (inhibits) | GABA agonist / glutamate antagonist | Depressant; disinhibition | Indirectly raises dopamine in reward pathway |
| Cannabis (THC) | Cannabinoid (CB1) receptors | Direct receptor stimulation | Altered perception; relaxation | Indirectly disinhibits VTA → dopamine |
Nicotine is a direct agonist at nicotinic acetylcholine receptors. By binding and activating these receptors it produces the alerting, mildly stimulating effect of smoking. Critically for dependence, nicotinic receptors sit on the dopamine-releasing neurons of the VTA; by stimulating them, nicotine increases dopamine release into the nucleus accumbens, engaging the reward pathway. This is why nicotine, despite modest subjective effects, is strongly reinforcing and hard to quit.
Cocaine is the clearest example of reuptake blockade. It binds the dopamine transporter and prevents the reabsorption of dopamine from the synaptic cleft, so dopamine accumulates and continues to stimulate postsynaptic receptors, producing intense euphoria and stimulation. Because its action is directly on the reward pathway's dopamine and because the effect is short-lived (as dopamine is eventually cleared), cocaine produces a rapid cycle of intense reward followed by craving — a profile associated with a high dependence risk. Its secondary blockade of serotonin and noradrenaline transporters contributes to its other effects.
Amphetamines act chiefly by increasing dopamine release and reversing the dopamine transporter, so dopamine pours into the synapse — a flooding rather than a mere accumulation. The result is a powerful, longer-lasting stimulant effect. MDMA (ecstasy) applies the same release/reversal mechanism but primarily to the serotonin system: it causes a massive release of serotonin (with a smaller effect on dopamine), producing the characteristic elevation of mood and feelings of emotional closeness (its "empathogenic" effect). The serotonin link is important synoptically, because the surge is followed by depletion — serotonin stores are temporarily exhausted — which is the neurochemical basis of the low mood ("comedown") reported in the days after use, and connects MDMA to the serotonin mechanisms discussed in the aggression lessons.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.